semaglutide and muscle pain GLP-1 Loss: Semaglutide, Tirzepatide & Lean Mass Ozempic May Make Your Muscles

The lag exists because the EMA has its own evidence requirements, including EU-specific safety data, and the European Commission must grant the final marketing authorization after the EMA issues a positive opinion

The GLP-1 receptor agonist market is growing rapidly, supported by rising obesity and diabetes prevalence, strong clinical outcomes, and increasing patient awareness

Adding a caloric deficit on top of declining estrogen and progesterone creates a fatigue picture that can feel overwhelming

For type 2 diabetes, GLP-1 receptor agonists are typically long-term therapies, similar to blood pressure or cholesterol medications

Progress is tracked inside the app over time